Joseph R. Moskal

Corporate Officer/Principal chez Northwestern University

73 ans

Consumer Services

Health Technology

Postes actifs de Joseph R. Moskal

Sociétés	Poste	Début	Fin
Northwestern University Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses	Corporate Officer/Principal	-	-

Sociétés	Poste	Début	Fin
Albert Einstein College of Medicine, Inc.	Corporate Officer/Principal	-	-
APTINYX	Directeur Technique/Scientifique/R&D	01/07/2015	-
	Fondateur	01/06/2015	-
	Corporate Officer/Principal	-	-
Naurex, Inc. Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.	Directeur Technique/Scientifique/R&D	13/05/2011	-
	Fondateur	01/01/2006	-

University of Notre Dame

Doctorate Degree

Internationale

Etats-Unis

Opérationnelle

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	2
Founder	2

Sectorielle

Consumer Services	4
Health Technology	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
APTINYX	Health Technology

Entreprise privées	1
Naurex, Inc. Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.	Health Technology

Entreprise privées

Health Technology